About Exact Sciences
Exact Sciences is a publicly listed company based in Madison (United States) founded in 1995, and was acquired by Abbott in March 2026. Non-invasive molecular diagnostic tests for cancer detection are provided. The company has 7,000 employees. Exact Sciences has completed 12 acquisitions, including Armune, Base Genomics and Biomatrica. Its chief executive, as recorded, is Kevin Conroy. Its website exactsciences.com draws about 546 thousand monthly visits. Its focus areas include Life Sciences, Oncology, In-Vitro Diagnostic Tests and Diversified. Its competitors include BridgeBio, Guardant Health and Spark Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Provider of non-invasive molecular diagnostic testing solutions for cancer. The flagship product includes Cologuard is intended for the qualitative detection of colorectal neoplasia-associated DNA markers and for the presence of occult hemoglobin in human stool to estimate a patients risk of developing colorectal cancer. Also, it offers an MCED blood test for multi-cancer detection.
- Headquarters Madison, United States
- Employees 7,000
- Stage Public
- SectorsHealthcare
- Website category Health
- Website exactsciences.com
- Social LinkedIn X Facebook
- Acquired by Abbott (Mar 2026)
- Legal Name Exact Sciences Corporation
- Annual Revenue$2.76 B (USD)10.37as on Dec 31, 2024
- Net Profit-$1.03 B (USD)-403.97as on Dec 31, 2024
- EBITDA$23.07 M (USD)130.21as on Dec 31, 2024
- Latest Funding Round$747.5M (USD), Post-IPO
Mar 2019
- InvestorsAbbott
& 1 more
- Employee Count7,000
- Investments & AcquisitionsArmune
& 11 more
- Acquired byAbbott
(Mar 2026)
Funding Insights of Exact Sciences
- Total Rounds 5
- Last Round Post-IPO — $747.5M
- First Round $8.2M
(Jun 2009)
- Investors Count 1
All 5 funding rounds of Exact Sciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2019 | $747.5M | Post-IPO | – | – | – |
| Jun 2018 | $233M | Post-IPO | – | – | – |
| Jun 2018 | $190M | Post-IPO | – | – | – |
| Jan 2018 | $690M | Post-IPO | – | – | |
| Jun 2009 | $8.2M | Post-IPO | – | – | – |
2 investors in total: 2 institutional.
Investors in Exact Sciences
Exact Sciences has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Abbott and Bank of America.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Commercial banking and asset management services are offered worldwide. | 1904 | bankofamerica.com | Charlotte, United States | |
Developer of medical devices, generic pharmaceuticals, and nutrition products | 1888 | abbott.com | Libertyville, United States |
Investor details for Exact Sciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Exact Sciences
636 people are tracked at Exact Sciences (188 in leadership, 9 in board & advisors, 439 in team); the tracked headcount is 7,000.
| Name | Role | Group |
|---|---|---|
Kevin Conroy | CEO | Leadership |
Michelle Beidelschies | Medical Affairs Director, Multi-cancer Early Detection - Thrive | Leadership |
Isaac Kinde | VP Technology Assessment | Leadership |
Anurag Gupta | Director, APAC - Indirect Markets | Leadership |
Jessica Angelos Castro | Emerging Capabilities, Strategic Innovation, And Partnerships- Growth Initiatives, Senior Director | Leadership |
Kristin Lamont | Director Medical Education & Information | Leadership |
Alex S. | Associate Director, International Accounting | Leadership |
Mark Hollenbeck | Associate Director, Enterprise Data | Leadership |
Patrick Tibbetts | Associate Director Of Data Engineering | Leadership |
Amir Khan | Chief Information Security Officer | Leadership |
Raj Pudipeddi | Chief Growth Officer | Leadership |
Sean Rollins | Director, IT Business Relationship Management - R&d And Corporate Strategy | Leadership |
Whitney Rusch | Director, Enterprise Platforms | Leadership |
Roman Mey | Director – Global IT Support Center Services | Leadership |
Courtney Cerdena | Sr. Director Of IT Solution Delivery | Leadership |
Matt Ford | Senior Director, Commercial Performance And Training | Leadership |
Rebeca Monsma | Principal Human Resources Business Partner | Leadership |
Bradley Arrick | Director, Oncology Medical Development | Leadership |
Eric Gagne | Lab Director | Leadership |
Bryan Maring | Director, Global Compliance Policy & Training | Leadership |
616 more people are available in the full profile.
Complete people profiles for Exact Sciences
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Exact Sciences
Exact Sciences is a publicly listed company on the NASDAQ with ticker symbol EXAS in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date12 Feb 2001
- Listed onNASDAQ: EXAS
- Listed entityExact Sciences Corporation
- Exchange sectorHealth technology
- ISINUS30063P1057
- Share price$104.91 (+0.95% on the day) · 2026-03-24
- Market capitalisation$20.03B
- EPS (diluted, trailing year)$-1.10
- Volume (last session)21,562,141
- Analyst consensusNeutral
Financials of Exact Sciences
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2024 | $2.76B | -$1.03B | $23.1M |
| 2023 | $2.50B | -$204.2M | -$76.4M |
| 2022 | $2.08B | -$623.5M | -$394.7M |
| 2021 | $1.77B | -$595.6M | -$523.0M |
| 2020 | $1.49B | -$823.6M | $21.7M |
Detailed financial statements for Exact Sciences
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Exact Sciences
Exact Sciences has strategically engaged in corporate development activities, having acquired 12 companies. Notable acquisitions include Armune, Base Genomics and Biomatrica.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Blood-based cancer diagnostics are developed via next-generation sequencing. | resolutionbio.com | Kirkland, United States | 2012 | Sep 2023 | •••• | |
Tools for protein data analysis are provided by OmicEra Diagnostics. | omicera.com | Munich, Germany | 2019 | May 2022 | $15M | |
Clinical gene sequencing services and duplication tests are provided. | preventiongenetics.com | Marshfield, United States | 2004 | Jan 2022 | $190M | |
Provider of cancer detection treatment guidance services | pfsgenomics.com | Michigan, United States | 2015 | May 2021 | $30.6M | |
Research and education are advanced by TGen. | tgen.org | United States | 2002 | Feb 2021 | •••• | |
In-vitro DNA methylation tests for early cancer detection are offered. | basegenomics.com | Oxford, United Kingdom | 2019 | Oct 2020 | •••• | |
Blood-based liquid biopsy tests for multiple cancer detection are provided. | thrivedetect.com | Cambridge, United States | 2019 | Oct 2020 | $2.15B | |
Precision diagnostics for identifying cancer mutations are developed. | paradigmdx.com | Phoenix, United States | 2012 | Mar 2020 | •••• | |
Provider of liquid biopsy tests for the detection of lung cancer | viomics.com | Phoenix, United States | 2011 | Mar 2020 | •••• | |
Genomic-based diagnostic tests for cancer prognosis are developed and provided. | genomichealth.com | Redwood, United States | 2000 | Jul 2019 | $2.8B |
Complete acquisition details for Exact Sciences
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Exact Sciences
15 dated milestones of Exact Sciences across 31 years, from founding to its latest funding, stage changes and deals.
- Founded Exact Sciences is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $8.2M.
- Funding Latest funding round, Post-IPO, of $747.5M.
- Acquisition Acquires Genomic Health.
- Acquisition Acquires Viomics.
- Acquisition Acquires Paradigm Dx.
- Acquisition Acquires Base Genomics.
- Acquisition Acquires Thrive Earlier Detection.
- Acquisition Acquires TGen.
- Acquisition Acquires PFS Genomics.
- Acquisition Acquires PreventionGenetics.
- Acquisition Acquires OmicEra Diagnostics.
- Acquisition Acquires Resolution Bioscience.
- Exit Acquired by Abbott.
Competitors of Exact Sciences
Exact Sciences has 3 listed competitors in our database, 3 of them funded. They include BridgeBio, Guardant Health and Spark Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| guardanthealth.com | 2012 | Redwood, United States | $557.5M | 1,351 | Digital sequencing technology for cancer detection is developed. | |
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. |
Detailed competitors of Exact Sciences
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Exact Sciences
The website of Exact Sciences (exactsciences.com) receives about 546.4K visits a month and ranks #82,917 among all websites worldwide, #2,370 in Health.
- Monthly visits546.4K
▲ 2% vs previous month
- Unique visitors270.3K
per month
- Global rank#82,917
among all websites
- Category rank#2,370
Health · Health
- Bounce rate41%
- Pages per visit3.5
- Average visit1 min 33 sec
- DevicesDesktop 42% · Mobile 58%
Websites whose visitors overlap most with Exact Sciences. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
exactsciences.sharepoint.com | exactsciences.sharepoint.com | 100% | – | ||
| exactlabs.com | 95% | 8K | #2,940,507 | View details | |
cologuardhcp.com | cologuardhcp.com | 90% | #1,171,694 | – | |
| abbott.com | 88% | 917.2K | #65,577 | View details | |
kustomerkinetics.com | kustomerkinetics.com | 87% | – | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for Exact Sciences
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Exact Sciences (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Exact Sciences
Complete news archive for Exact Sciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Exact Sciences
Exact Sciences was founded in 1995 and raised its 1st funding round 14 years after it was founded.
Exact Sciences is headquartered in Madison, United States. It is registered at Madison, Wisconsin, United States.
Kevin Conroy is the CEO of Exact Sciences, as recorded in our data.
Exact Sciences has 7,000 employees.
Annual revenue of Exact Sciences is $2.76B as on Dec 31, 2024.
Provider of non-invasive molecular diagnostic testing solutions for cancer. The flagship product includes Cologuard is intended for the qualitative detection of colorectal neoplasia-associated DNA markers and for the presence of occult hemoglobin in human stool to estimate a patients risk of developing colorectal cancer. Also, it offers an MCED blood test for multi-cancer detection.
Exact Sciences's top competitors include Guardant Health, Spark Therapeutics and BridgeBio.
Yes, Exact Sciences is publicly traded on NASDAQ under the ticker symbol EXAS.
Exact Sciences has made 12 acquisitions, including Armune, Base Genomics, and Biomatrica.
Exact Sciences has 2 investors. Key investors include Abbott, and Bank of America.
Yes. Exact Sciences was acquired by Abbott in March 2026.
The website of Exact Sciences receives about 546 thousand visits a month and ranks #82,917 among all websites worldwide.